Skip to main content
OpenTrials

Clinical trial condition

Dyskinesias

Explore clinical trials studying Dyskinesias. Study availability and eligibility vary by location and protocol.

22 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Dyskinesias trial results

Completed

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491932

Conditions
Anti-Dyskinesia Agents, Basal Ganglia Diseases, Brain Diseases, +11 more
Locations
  • Novartis Investigative Site Englewood, Colorado, United States
  • Novartis Investigative Site Kansas City, Kansas, United States
  • Novartis Investigative Site Milwaukee, Wisconsin, United States
  • Novartis Investigative Site Innsbruck, Austria
View all 32 locations
View Trial Details
Completed

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491529

Conditions
Anti-Dyskinesia Agents, Basal Ganglia Diseases, Brain Diseases, +11 more
Locations
  • Novartis Investigative Site Sunnyvale, California, United States
  • Novartis Investigative Site Englewood, Colorado, United States
  • Novartis Investigative Site Tampa, Florida, United States
  • Novartis Investigative Site Kansas City, Kansas, United States
View all 39 locations
View Trial Details
Completed

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01385592

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +10 more
Locations
  • Novartis Investigative Site Sunnyvale, California, United States
  • Novartis Investigative Site Englewood, Colorado, United States
  • Novartis Investigative Site London, Ontario, Canada
  • Novartis Investigative Site Gatineau, Quebec, Canada
View all 28 locations
View Trial Details
Completed

Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT00986414

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +10 more
Locations
  • Novartis Investigative Site East Gosford, Australia
  • Novartis Investigative Site Heidelberg, Australia
  • Novartis Investigative Site Melbourne, Australia
  • Novartis Investigative Site Parkville, Australia
View all 47 locations
View Trial Details
Completed

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

NCT00363727

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +11 more
Locations
  • GSK Investigational Site Anniston, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
View all 69 locations
View Trial Details
Completed

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

NCT00360568

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +12 more
Locations
  • Site Reference ID/Investigator# 45869 Birmingham, Alabama, United States
  • Site Reference ID/Investigator# 45834 Fountain Valley, California, United States
  • Site Reference ID/Investigator# 45854 Los Angeles, California, United States
  • Site Reference ID/Investigator# 45856 Oceanside, California, United States
View all 22 locations
View Trial Details

Related conditions